Tonghua Dongbao Pharmaceutical Co., Ltd. Class A

Tonghua Dongbao Pharmaceutical Co., Ltd. Class A

SSSE:600867
7.73
CNY
+0.09
(+1.18%)
0.25EPS
28.74P/E
15.39BMarket Cap
Apr 22Next Earn

Total Valuation

CNY

As of September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A carries a market capitalization of 15.39B, placing it among publicly traded companies globally. Its enterprise value stands at 14.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap15.39B
Enterprise Value14.39B

Important Dates

Tonghua Dongbao Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 22, 2027.

Earnings Date4/22/2027

Share Statistics

As of September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A has 1.96B shares outstanding.

Shares Outstanding1.96B

Valuation Ratios

As of September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 28.74. The price-to-sales ratio is 4.82, and the price-to-book ratio stands at 2.17.

PE Ratio28.74
PS Ratio4.82
PB Ratio2.17
P/TBV Ratio2.87

Enterprise Valuation

As of September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 20.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 14.39B versus a market cap of 15.39B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.45
EV / EBITDA20.46
EV / EBIT20.46

Financial Position

As of September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A maintains a current ratio of 4.19, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.33, indicating elevated leverage, while an interest coverage ratio of 38.84 demonstrates strong ability to service its debt obligations.

Current Ratio4.19
Quick Ratio2.31
Debt / Equity9.33
Debt / EBITDA0.94
Interest Coverage38.84

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 8.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.24 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.81, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.17, useful for judging operating efficiency across full business cycles. The company generates approximately 964,952.28 in revenue per employee across its workforce of 3,354.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.43 indicates how many times Tonghua Dongbao Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)8.21
Return on Assets (ROA)6.81
Return on Invested Capital (ROIC)7.24
Return on Capital Employed (ROCE)8.17
Revenue Per Employee964,952.28
Employee Count3,354.00
Inventory Turnover1.43

Taxes

CNY

Over the twelve months ended September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A recorded 155.43M in income tax expense. That works out to an effective tax rate of 23.83, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 652.21M, leaving 542.23M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax155.43M
Effective Tax Rate23.83

Stock Price Statistics

CNY

As of the close on November 17, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A's stock has declined approximately 14.30% over the past 52 weeks. The 50-day moving average sits at 7.84, while the 200-day moving average is 8.45.

52-Week Price Change-14.30%
50-Day Moving Average7.84
200-Day Moving Average8.45

Income Statement

CNY

Over the twelve months ended September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A generated 3.24B in revenue and converted that into 542.23M in net income, yielding earnings per share of 0.25. EBITDA reached 703.33M, while operating income came in at 819.01M.

Revenue3.24B
Gross Profit2.25B
Operating Income819.01M
Pretax Income652.21M
Net Income542.23M
EBITDA703.33M
EBIT703.33M
Earnings Per Share (EPS)0.25

Balance Sheet

CNY

As of September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A holds 1.63B in cash and equivalents against 658.58M in total debt, resulting in a net debt position of -684.66M. Total book value stands at 7.09B, with working capital of 2.26B providing operational flexibility.

Cash & Cash Equivalents1.63B
Total Debt658.58M
Net Debt-684.66M
Equity (Book Value)7.09B
Book Value Per Share3.62
Working Capital2.26B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-506.49M

Margins

Over the twelve months ended September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A posted a gross margin of 69.67, reflecting its pricing power and cost economics. The operating margin of 25.31 and net profit margin of 16.75 provide insight into operational efficiency.

Gross Margin69.67
Operating Margin25.31
Pretax Margin20.15
Profit Margin16.75
EBITDA Margin21.73

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A paid dividends of 0.31 per share. The dividend payout ratio of 135.28 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.94, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tonghua Dongbao Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.31
Payout Ratio135.28
Shareholder Yield4.94

Stock Splits

Tonghua Dongbao Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 25, 2018 with a 5:6 split ratio.

Last Split Date5/25/2018
Split Ratio5:6

Scores

As of September 30, 2026, Tonghua Dongbao Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 11.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score11.36